Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy
Simone Krebs, Joseph A. O’Donoghue, Evan Biegel, Bradley J. Beattie, Diane Reidy‐Lagunes, Serge K. Lyashchenko, Jason S. Lewis, Lisa Bodei, Wolfgang Weber, Neeta Pandit‐Taskar
Topics & Concepts
Radionuclide therapyDOTAMedicineNuclear medicineNeuroendocrine tumorsPET-CTLesionPositron emission tomographyRadiologyInternal medicinePathologyIn vivoBiotechnologyBiologyNeuroendocrine Tumor Research AdvancesLung Cancer Research StudiesNeuroblastoma Research and Treatments